TechMARK movers: Oxford Biomedica plans clinical trials

29th Oct 2010 12:54

Shares in gene therapy developer Oxford Biomedica have edged down even though it said that it expects six of its products to commence clinical trials next year. Net cash has reduced by £2.6m to £13.7m in the three months to September 2010. That cash should last until the beginning of 2012. Broker Singer has initiated coverage of Oxford Biomedica. It believes that Oxford Biomedica is worth 17p a share. That is based on the broker's views on how much cancer vaccine TroVax, Parkinson's disease treatment ProSavin and degeneration prevention treatment RetinoStat are worth. Biocompatibles is one of the very few TechMARK companies to rise today. This follows a positive study supporting the use of MoleMate, a non-invasive melanoma visualisation and assessment device, used to diagnose melanoma. FTSE TechMARK - RisersRenovo Group (RNVO) 33.75p +3.05%Optos (OPTS) 108.00p +1.89%Vislink (VLK) 20.25p +1.25%Biocompatibles International (BII) 365.00p +0.41%FTSE TechMARK - FallersVernalis (VER) 44.00p -5.38%ProStrakan Group (PSK) 71.50p -3.38%Oxford Biomedica (OXB) 9.71p -2.71%XP Power Ltd. (DI) (XPP) 1,002.00p -2.24%Emblaze Ltd. (BLZ) 44.25p -2.21%BAE Systems (BA.) 340.90p -2.15%Filtronic (FTC) 35.00p -2.10%Gresham Computing (GHT) 26.50p -1.85%Vodafone Group (VOD) 168.20p -1.46%Axis-Shield (ASD) 257.00p -1.15%